A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

BACKGROUND: Fragile X syndrome (FXS) is associated with dysregulated endocannabinoid signaling and may therefore respond to cannabidiol therapy. DESIGN: CONNECT-FX was a double-blind, randomized phase 3 trial assessing efficacy and safety of ZYN002, transdermal cannabidiol gel, for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Berry-Kravis, Elizabeth, Hagerman, Randi, Budimirovic, Dejan, Erickson, Craig, Heussler, Helen, Tartaglia, Nicole, Cohen, Jonathan, Tassone, Flora, Dobbins, Thomas, Merikle, Elizabeth, Sebree, Terri, Tich, Nancy, Palumbo, Joseph M., O’Quinn, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700889/
https://www.ncbi.nlm.nih.gov/pubmed/36434514
http://dx.doi.org/10.1186/s11689-022-09466-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700889/
https://www.ncbi.nlm.nih.gov/pubmed/36434514
http://dx.doi.org/10.1186/s11689-022-09466-6

Ejemplares similares